Diagnosing familial amyotrophic lateral sclerosis involves a combination of clinical evaluation, specialized tests to rule out other conditions, and genetic testing to identify inherited mutations. Since approximately 10% of ALS cases run in families, early and accurate diagnosis becomes especially important for affected individuals and their relatives who may carry disease-causing genetic changes.

Introduction: Who Should Seek Diagnostic Testing

People who should consider diagnostic evaluation for familial amyotrophic lateral sclerosis include those experiencing progressive muscle weakness, stiffness, or twitching, particularly if they have a family history of ALS or related motor neuron disease. Early symptoms can be subtle and easily overlooked, often beginning with muscle weakness or stiffness in the arms and legs, as well as difficulties with speech and swallowing. These initial signs can make everyday tasks like writing, eating, or walking more challenging, and they typically spread throughout the body over time.^[4]

Individuals with a known family history of ALS should be particularly vigilant about seeking medical attention when neurological symptoms appear. Familial ALS, which accounts for about 10% of all ALS cases, typically develops earlier than sporadic ALS, with symptoms often appearing in a person’s late forties or early fifties rather than in their sixties.^[3] This earlier onset means that people with affected family members may benefit from earlier screening and genetic counseling, even before symptoms develop.

It is advisable to seek diagnostic evaluation promptly when symptoms first appear because early diagnosis can lead to earlier intervention. While the speed at which symptoms progress varies significantly from person to person, getting an accurate diagnosis allows healthcare providers to develop a comprehensive care plan, connect patients with support services, and potentially enroll them in clinical trials. Additionally, for family members of someone diagnosed with familial ALS, genetic testing and counseling can provide valuable information about their own risk.^[5]

Classic Diagnostic Methods

Diagnosing amyotrophic lateral sclerosis can be challenging in its early stages because symptoms often resemble those of other neurological conditions. Healthcare providers use multiple diagnostic approaches to confirm ALS and rule out other diseases that might cause similar symptoms. The diagnostic process typically involves a thorough clinical examination combined with several specialized tests.^[11]

Clinical Neurological Examination

The diagnostic journey usually begins with a comprehensive neurological examination by a specialist. During this evaluation, the doctor assesses muscle strength, reflexes, coordination, and signs of muscle wasting. They look for specific patterns that suggest damage to both upper motor neurons in the brain and lower motor neurons in the spinal cord, which is characteristic of ALS. The physician will also review the patient’s medical history and family history in detail, as knowing whether other family members have had ALS or related conditions provides crucial diagnostic information.^[4]

Electromyography and Nerve Conduction Studies

Electromyography, commonly known as EMG, is one of the most important tests for diagnosing ALS. During this procedure, a thin needle electrode is inserted through the skin into various muscles throughout the body. The test records the electrical activity produced by muscles both when they contract and when they are at rest. This helps doctors determine whether there is a problem originating in the muscles themselves or in the nerves that control them.^[11]

EMG is almost always performed together with nerve conduction studies, which measure how well nerves can send electrical impulses to muscles in different areas of the body. These studies can help identify nerve damage and distinguish ALS from other conditions affecting the nervous system. Together, these electrical tests provide critical information about the health and function of motor neurons and can reveal patterns consistent with ALS.^[11]

Magnetic Resonance Imaging

Magnetic resonance imaging, or MRI, uses powerful magnetic fields and radio waves to create detailed images of the brain and spinal cord. While MRI cannot directly diagnose ALS, it plays a vital role in the diagnostic process by helping doctors rule out other conditions that might cause similar symptoms. An MRI can reveal spinal cord tumors, herniated disks in the neck, or other structural problems that could be responsible for the patient’s symptoms. The highest resolution MRI scanners may sometimes detect changes associated with ALS itself, though this is not always the case.^[11]

Blood and Urine Tests

Laboratory analysis of blood and urine samples helps eliminate other possible causes of symptoms that might mimic ALS. These tests can identify conditions such as thyroid disease, vitamin deficiencies, infections, or immune system disorders that might produce similar neurological symptoms. Importantly, blood tests can also measure levels of neurofilament light chain, a protein that is generally elevated in people with ALS. This biomarker can help support an ALS diagnosis early in the disease process.^[11]

Spinal Tap (Lumbar Puncture)

A spinal tap, also called a lumbar puncture, involves removing a small sample of spinal fluid for laboratory testing. During this procedure, a thin needle is carefully inserted between two bones in the lower back to collect the fluid. In people with ALS, the spinal fluid typically appears normal, but the test is valuable because it can uncover alternative diagnoses. Certain infections, inflammatory conditions, or other neurological diseases can be identified through spinal fluid analysis, helping doctors be more confident in an ALS diagnosis when these other conditions are ruled out.^[11]

Muscle Biopsy

If a healthcare provider suspects that symptoms might be caused by a muscle disease rather than ALS, they may recommend a muscle biopsy. This procedure involves removing a small sample of muscle tissue for microscopic examination. While not routinely performed in ALS diagnosis, muscle biopsy can help distinguish between motor neuron disease and primary muscle disorders that might present with similar weakness.^[11]

Genetic Testing for Familial ALS

Genetic testing has become an increasingly important component of diagnosing familial ALS, particularly over the past two decades. Since the discovery in 1993 that mutations in the SOD1 gene can cause familial ALS, researchers have identified more than 40 genes associated with inherited forms of the disease. Understanding which genetic mutation a patient carries has important implications for family members, treatment options, and eligibility for specialized clinical trials.^[1][4]

Common Genes Tested in Familial ALS

Several genes are most frequently associated with familial ALS. The C9orf72 gene is among the most common causes, though its frequency varies significantly by ethnicity and geography. In Europe and the United States, C9orf72 mutations account for 30 to 40 percent of familial cases, but this mutation is much less common in Japan and other Asian populations. The SOD1 gene, which was the first ALS gene identified, accounts for 13 to 20 percent of familial cases and is relatively more common in Japanese populations compared to C9orf72.^[3][6]

Other important genes include FUS and TARDBP, which encode proteins involved in processing genetic material within cells. When these genes contain disease-causing mutations, they lead to the production of abnormal proteins that damage motor neurons. Genetic testing typically screens for mutations in these and other known ALS-related genes to determine whether a patient has a hereditary form of the disease.^[4][6]

Inheritance Patterns

Most familial ALS follows an autosomal dominant inheritance pattern, meaning that a person needs only one copy of the mutated gene from one parent to develop the disease. Each child of an affected parent has a 50 percent chance of inheriting the mutation. This pattern explains why familial ALS often appears in multiple generations of the same family. However, not everyone who inherits a disease-causing mutation will necessarily develop symptoms, and the age at which symptoms begin can vary even within the same family.^[5][6]

Benefits and Process of Genetic Testing

For people diagnosed with ALS who have a family history of the disease, genetic testing can confirm whether their condition is caused by an inherited mutation. This information is valuable for several reasons. First, it helps family members understand their own risk and make informed decisions about whether they want to pursue predictive genetic testing. Second, knowing the specific genetic cause can open doors to targeted treatments. For example, individuals with SOD1 mutations are eligible for a specialized medication called tofersen, which was specifically developed to target the abnormal SOD1 protein.^[6][8]

The genetic testing process typically begins with genetic counseling, where a trained professional explains what the test involves, what the results might reveal, and how this information could affect the patient and their family. If the patient decides to proceed, a blood sample is collected and sent to a specialized laboratory for analysis. Results usually take several weeks to return. Follow-up genetic counseling helps patients understand their results and discuss next steps.^[5]

Testing for Presymptomatic Family Members

Family members of someone with familial ALS may choose to undergo genetic testing even if they have no symptoms. This is called presymptomatic or predictive testing. Knowing whether they carry a disease-causing mutation allows individuals to make informed decisions about their future, participate in research studies, and potentially access preventive treatments if they become available. Currently, clinical trials are enrolling presymptomatic carriers of SOD1 mutations to test whether early treatment with tofersen can delay or prevent the onset of ALS symptoms.^[8]

Diagnostics for Clinical Trial Qualification

As research into familial ALS advances, clinical trials have become an important avenue for accessing experimental treatments that may not yet be widely available. However, enrolling in a clinical trial requires meeting specific diagnostic criteria to ensure that the study results are reliable and that participants are likely to benefit from the experimental intervention. The diagnostic tests used for trial qualification often go beyond standard clinical diagnosis.^[6]

Genetic Confirmation Requirements

Many clinical trials for familial ALS require participants to have confirmed genetic mutations in specific genes. For example, trials testing gene-targeted therapies, such as antisense oligonucleotides designed to reduce production of toxic proteins, typically enroll only patients with mutations in the gene being targeted. The trial that led to approval of tofersen enrolled individuals who had confirmed mutations in the SOD1 gene. Participants need documented genetic test results showing they carry a disease-causing SOD1 variant before they can join such studies.^[6][8]

This requirement for genetic confirmation means that potential trial participants must undergo comprehensive genetic testing if they haven’t already done so. Some trials may also require testing to be repeated or confirmed at a specific laboratory to ensure accuracy and consistency in how genetic variants are identified and classified.

Disease Severity and Progression Measures

Clinical trials often use standardized measures to assess disease severity and rate of progression as criteria for enrollment. These measurements help researchers ensure that participants are at an appropriate stage of disease for the intervention being tested and provide baseline data for measuring treatment effects. Common measures include the ALS Functional Rating Scale, which scores a patient’s ability to perform various daily activities, from speaking and swallowing to walking and breathing.

Trials may also require baseline measurements of respiratory function through pulmonary function tests, which measure how well the lungs are working. These tests are important because breathing difficulties are a major concern in ALS, and many treatments aim to slow the decline in respiratory function. Participants might need to have respiratory function above or below a certain threshold to qualify for specific trials.

Biomarker Measurements

Research into biomarkers has identified substances that can be measured in blood or spinal fluid to assess disease activity. One important biomarker is neurofilament light chain, a protein released when neurons are damaged. Elevated levels of this protein in the blood generally indicate active motor neuron degeneration. Some clinical trials use neurofilament levels as an enrollment criterion or as an outcome measure to assess whether a treatment is slowing neuronal damage.^[6][11]

For certain trials, participants may need to undergo lumbar puncture to obtain spinal fluid for biomarker analysis. While more invasive than a blood test, spinal fluid provides valuable information about what is happening in the central nervous system and can reveal whether an experimental treatment is having its intended biological effect.

Presymptomatic Enrollment

An emerging area of clinical trial research involves enrolling individuals who carry ALS-causing genetic mutations but have not yet developed symptoms. These presymptomatic trials aim to determine whether early intervention can delay or prevent disease onset. For these studies, diagnostic criteria focus on confirming the genetic mutation while also demonstrating that the individual does not yet show clinical signs of ALS through comprehensive neurological examination and functional assessments.^[8]

One such trial, called ATLAS, is currently enrolling presymptomatic carriers of SOD1 mutations to test whether tofersen can prevent or delay symptom onset. Individuals interested in these trials need genetic testing and counseling to confirm they carry a relevant mutation, followed by thorough evaluation to document that they are presymptomatic. This approach represents hope that future generations of families affected by ALS might be able to prevent the disease rather than just treat it after symptoms appear.